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Dose Escalation Pharmacokinetics of
Intranasal Scopolamine Gel Formulation
Lei Wu, BS1, Jason L. Boyd, PhD2, Vernie Daniels, MS, RPh3, Zuwei Wang, PhD3,
Diana S-L. Chow, PhD1, and Lakshmi Putcha, PhD4
Abstract
Astronauts experience Space Motion Sickness requiring treatment with an anti-motion sickness medication, scopolamine during space missions.
Bioavailability after oral administration of scopolamine is low and variable, and absorption form transdermal patch is slow and prolonged. Intranasal
administration achieves faster absorption and higher bioavailability of drugs that are subject to extrahepatic, first passmetabolism after oral dosing.We
examined pharmacokinetics of 0.1, 0.2, and 0.4mg doses of the Investigational New Drug formulation of intranasal scopolamine gel (INSCOP) in 12
healthy subjects using a randomized, double-blind cross-over study design. Subjects received one squirt of 0.1 g of gel containing either 0.1mg or
0.2mg/0.1mL scopolamine or placebo in each nostril. Serial blood samples and total urine voids were collected after dosing and drug concentrations
were determined using a modified LC-MS-MS method. Results indicate dose-linear pharmacokinetics of scopolamine with linear increases in Cmax and
AUC within the dose range tested. Plasma drug concentrations were significantly lower in females than in males after administration of 0.4 dose. All
three doses were well tolerated with no unexpected or serious adverse side effects reported. These results suggest that intranasal scopolamine gel
formulation (INSCOP) offers a fast, reliable, and safe alternative for the treatment of motion sickness.
Keywords
scopolamine, intranasal, pharmacokinetics, dose escalation
Of all the neurovestibular disturbances experienced by
astronauts immediately after exposure to the microgravity
environment of space flight, Space Motion Sickness
(SMS) causes acute symptoms and discomfort requiring
treatment with medications during the early, mission
critical time of space flight. Nearly 40% of all medications
used by astronauts during flight has been for the treatment
of SMS.1
Approximately 70% of Space Shuttle crewmembers
experience symptoms of SMS during the first few days of
flight. These symptoms can include malaise, anorexia,
headache, lack of motivation, impaired concentration,
stomach awareness, and vomiting.2,3 The severity of these
symptoms can be debilitating and are most severe early in
spaceflight beginning on the first day of microgravity and
continuingforseveraldays;later inflight, frequencyofSMS
andseverityofsymptomsappeartodiminish.Thefrequency
and severity of SMS symptoms have led to restrictions on
extravehicular activities (no sooner than 72 hours after
launch) and mission duration (no less than 3 days).
Astronauts use a variety of medications to prevent or
reduce severity of SMS symptoms. Promethazine (PMZ)
has been the primary pharmacologic countermeasure used
to treat SMS since 1988 and, although effective, it has
long-lasting side effects that include drowsiness and dry
mouth. Seventy five percent (75%) of crewmembers who
take PMZ during flight experience drowsiness.3 The
sedative side effect is undesirable and potentially
dangerous during missions especially in an emergency,
or during other mission-critical activities like Shuttle-
station docking which demand optimal alertness and
cognitive function. Similarly, another commonly used
medication for motion sickness, diphenhydramine, also
has sedative side effects. Although it is perceived by the
crew that the benefit of PMZ treatment for SMS
outweighs the risk from sedative side effects of the
drug, a potential for untoward adverse event still exists.
Scopolamine is a historically known belladonna
alkaloid used as an anticholinergic/antiemetic for a long
time. It is a very common prescription medication for the
prevention of nausea and vomiting associatedwithmotion
sickness. Earlier reports indicate that scopolamine is the
most effective drug for suppressing nausea and vomiting
caused by motion sickness.4–6 Wood and Graybiel7
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Pharmacokinetics
compared 16 drugs and drug combinations administered
orally for the prevention of motion sickness induced by
slow rotating room and found the most effective treatment
for motion sickness to be a combination dose of
scopolamine and dextroamphetamine. Another recent
study also compared the efficacy of current choices of
motion sickness medications and reported that scopol-
amine was the most efficacious treatment for suppression
of both nausea and vomit reflex induced by Vertical
Rotating Chair (VRC). Of the medications tested in the
study, only scopolamine had a positive treatment effect of
prolongation ofmean duration of rotation time in the VRC.
Additionally, accuracy of Delayed Matching-to-Sample
Test (DMTST), a short term memory and attention test,
was found to be unaffected by scopolamine whereas other
medications negatively affected DMTST scores; these
results confirm that scopolamine does not impair cognitive
performance like the others tested in this study.8 Based on
these scientific reports and operational experience from the
Navy, NASA’s Reduced Gravity Office uses scopolamine
tablets (0.8mg) and scopolamine combined with dextro-
amphetamine (0.8/10mg) dispensed in a capsule for the
treatment of motion sickness on board DC-9 parabolic
flights, a microgravity analog environment for training
astronauts and testing flight equipment.
Scopolamine has been reported to have a low absolute
bioavailability of approximately 4% from an oral dose given
as a tablet9 because of extensive first pass metabolism of the
drug after oral administration. A tablet formulation, Scopase,
an over the countermedication, is no longer available, and the
transdermal patch is available by prescription for use by
travelers who may experience low to medium severity of
motion sickness. The patch is a low dose, sustained release
dosage form intended for treatment over a long period of
3 days. Despite the ease of use and convenience of
transdermal patches, they have been notoriously inconsistent
in rate and amount of drug released.10
In addition to SMS symptoms which affect oral
bioavailability of drugs, spaceflight is also known to
influence gastrointestinal (GI) function by reducing GI
motility.11 To alleviate this reduction in bioavailability,
an aqueous intranasal dosage form of scopolamine was
compounded and absolute bioavailability assessed in
healthy human subjects in a phase I Investigational New
Drug (IND) study under FDA sponsorship. Results of this
study indicated that intranasal administration of scopol-
amine facilitates rapid absorption with significantly
higher and more reliable absolute bioavailability than
an equivalent oral dose (83% vs 3.7%, P < 0.05).9 In this
Phase II IND study, we examined pharmacokinetics after
administration of a custom manufactured intranasal
scopolamine gel formulation (INSCOP). This FDA
sponsored clinical trial was designed to characterize
dose linearity of INSCOP for optimizing dose range and
dosing interval to facilitate clinical trials to establish
safety and efficacy of treatment for motion sickness with
this IND formulation.
Subjects and Methods
The clinical protocol was reviewed and approved by the
NASA Johnson Space Center Committee for the Protec-
tion of Human Subjects and the Investigational Review
Board of MDS Pharma Services (Lincoln, Nebraska)
where this IND clinical protocol was implemented.
Twelve healthy, non-smoking human subjects between
21 and 47 years of age with matching astronaut’s age
group participated in the study after giving a written
informed consent briefing. Subjects were brought into the
MDS research clinic on the night before for an overnight
stay and were given the first dose at approximately 8 AM
the next morning. Subjects who had a history of nasal
surgery were excluded from the study. Caffeinated
beverages and grapefruit containing products were
restricted during the study period. Fluid intake was
monitored on study days to maintain adequate hydration.
Treatments
Two intranasal gel formulations with 0.1 and 0.2mg of
scopolamine hydrobromide in 0.1 g of gel were custom
manufactured by Nastech Pharmaceuticals, Inc., Bothell,
Washington and were dispensed in actuator pumps
(Pfeiffer of America, Princeton, New Jersey). The carrier
gel was custom compounded as a proprietary undisclosed
formulation by Nastech. A fully randomized double blind
crossover study design was used for drug and placebo
treatments with a seven-day washout period between
treatments. Each subject received three doses of scopol-
amine, 0.1, 0.2, and 0.4mg and a placebo and order of
treatments was randomized amongst subjects. Treatments
were administered following an 8–10 hour overnight fast
starting at bed time on the day before each treatment. All
treatments were administered by a study nurse to deliver
one squirt of the gel into each nostril; for 0.1mg dose,
subjects received a squirt of placebo in one of the nostrils.
Serial blood samples (7mL) were collected at 0, 0.083,
0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24 h after each
treatment into heparinized vacutainers from an indwelling
catheter (Intracath1, Becton and Dickinson, Downers
Grove, Illinois) placed in the antecubital vein in the arm.
Samples were gently mixed by inversion and centrifuged
at 3,000 rpm to separate plasma, transferred into
cryotubes, and stored frozen at 40 °C until analysis.
Urine voids were collected at scheduled time intervals
from 5min to 24 h after dosing. Samples were stored
frozen at 80 °C until analyzed.
Sample Analysis
Concentrations of scopolamine in plasma and urine were
measured by a modified LC-MS/MS method.12 Plasma
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samples were extracted with ice cold acetonitrile and drug
concentrations determined using Waters1 LCMSMS
system (Waters Corporation, Milford, Massachusetts).
Briefly, separation and quantitation of scopolamine
concentrations in the sample extracts was achieved using
a Waters Acquity UPLC system combined with Micro-
mass Quattro MicroTM API MS/MS detector using an
electrospray interface. Positive ions weremonitored in the
Multiple Reaction Monitoring (MRM) mode. Chro-
matographic separation was accomplished with an
Agilent Zorbax SB-CN 50 2.1mm, 5mm, column and
a mobile phase of 90:10 (v/v), methanol: 2mM
ammonium acetate, pH adjusted to 5.0 0.1, with a
flow rate of 0.2mL/min, injection volume of 10mL, and
run time of 4minutes. Precision and accuracy of the assay
were acceptable with r2¼ 0.99 or better for the linearity
established by the regression of response areas across the
detected concentrations range between 100 and 1000 pg/
mL with LLOQ of 50 pg/mL. Inter- and intra-day
coefficients of variation were below 10%. The extraction
recoveries were 77.2% for 100 pg/mL and 86.4% for
1000 pg/mL and the coefficient of variation for percent
extraction recovery was below 5% at all concentrations.
Scopolamine glucuronide levels in the urine were
determined by difference between unconjugated and total
scopolamine concentration. Total scopolamine concen-
tration consisting of unconjugated parent drug and
glucuronide conjugate was determined after incubation
of samples with b-glucuronidase at 37 °C for 12 h to
cleave scopolamine and glucuronide before solid phase
extraction.
Data Analysis
Plasma concentration versus time data were fitted to a one-
compartment model using WinNonlin (version 6.3,
Mountain View, CA) to estimate pharmacokinetic param-
eters.13 Area under the curve was determined by trapezoid
rule by extrapolation to infinity from the last predicted time
point using the terminal elimination rate. Dose linearity of
areamoment pharmacokinetic parameters was tested using
SAS proc glm (Cary, North Carolina). Differences of PK
parameters between sexes were determined using a non-
parametric Wilcoxon–Mann–Whitney test, with level of
significance set at a¼ 0.05.
Urinary excretion data were analyzed by non-
compartmental analysis using WinNonlin (version 6.3)
to estimate pharmacokinetic parameters.
Results
All subjects hadnormal values forhepatic and renal functions
(albumin, ALT, ALP, AST, bilirubin, BUN, hematocrit,
GGT, urinary creatinine clearance) as well as indices of
cardiovascular function (blood pressure, pulse rate). Details
of subject demographics are presented in Table 1.
Side Effects Profile
The INSCOP was well tolerated with no reports of
clinically significant unexpectedadverse events.Vital signs
were not significantly different among treatments. The
most commonly reported Expected Adverse Event was
sleepiness or drowsiness whichwas experienced by nine of
twelve subjects and this effect was not statistically
correlated with dose. Three female subjects reported
dizziness or lightheadedness within three hours after
dosing of 0.4mg. Two other female subjects reported
nasal burning within 10minutes after dosing, one after a
0.2mg dose and another after the 0.4mg dose. One female
subject reported aftertaste within fifteen minutes of dosing.
All of these minor discomforts were resolved within
30minutes after dosing.
Pharmacokinetics
Mean plasma concentration versus time profiles for the
three doses of scopolamine in 12 subjects are presented
in Figure 1(a) and separately for males and females in
Figures 1(b) and (c), respectively. Absorption of the
drug was fast, reaching maximum plasma concentra-
tions within one hour after dosing, and declined
exponentially thereafter reaching concentrations below
the LLOQ of 50 pg/mL in most subjects in 6 hours after
the 0.1mg dose, in 8 hours after the 0.2mg dose, and
12 hours after the 0.4mg dose. Increase in Cmax and
AUC were linear with dose administered (Figure 2,
r2¼ 0.99). Mean values of pharmacokinetics parameters
calculated for the three dose levels are presented in
Table 2. These data suggest that there are no significant
differences between sexes after 0.1 and 0.2mg dosing.
However, after administration of 0.4mg dose, mean
maximum plasma concentration (Cmax) of INSCOP in
males was lower than that in females (P< 0.05);
clearance and volume of distribution in males were
higher than in females (P< 0.05).
Urinary excretion rate profiles of scopolamine as a
function of time after administration for all three doses are
presented in Figure 3; amount excreted in the urine as
scopolamine and its glucuronide metabolite after admin-
istration of the three doses are presented in Table 3. The
percentage of dose excreted in the urine as scopolamine
Table 1. Demographics of Study Subjects
Gender Male Female
N 6 6
Age (mean SD) 37 8.5 29 5.4
Body weight (mean SD) 88.7 9.6 72.8 14.3
Average BMI 26
SD, standard deviation; BMI, body mass index.
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was consistent for all three doses, with less than 1.5% of
the administered dose being eliminated unchanged
confirming that hepatic metabolism, not renal excretion
is the major pathway for elimination of scopolamine in
humans. However, the percentage of dose excreted as
scopolamine glucuronide, a significant metabolite excret-
ed in the urine was less than 5.2% of all doses, suggesting
existence of other metabolites from hepatic metabolism
Figure 1. Mean plasma concentration versus time profiles of scopolamine after administration of INSCOP to normal subjects (mean SE). (a) Mean
plasma concentration profiles of scopolamine in all subjects (n¼ 12), (b) mean plasma concentration profiles of scopolamine in male subjects (n¼ 6),
(c) mean plasma concentration profiles of scopolamine in female subjects (n¼ 6).
Figure 2. Absorption parameters of scopolamine as a function of dose after administration of INSCOP to normal subjects (mean SE). (a) Cmax vs.
Dose, (b) Cmax/D (dose* body wt.) vs. Dose, (c) AUC vs. Dose, (d) AUC/D (dose*body wt.) vs. Dose.
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and/or from extra-hepatic pathways of metabolism of
scopolamine in humans.
Discussion
Scopolamine is a legacy drug used for the treatment of
motion sickness in the military, NASA manned space-
flight program, and in the global settings as one of the first
drugs approved for marketing by the US FDA. It has a
long standing safety profile established in its currently
marketed formulations for multiple indications with
decades of post marketing drug safety evaluations.
Current doses and dosage regimens of scopolamine are
considered safe although care should be exercised when
taking higher than recommended doses due to detrimental
side effects which include drowsiness, memory im-
pairment, dry mouth, and mydriasis.
At present, scopolamine transdermal patch is the only
non-invasive formulation available on the market for the
treatment of motion sickness. Doweck et al14 investigated
the rate of scopolamine absorption through the skin and
reported that therapeutic levels of scopolamine were
achieved only 5–6 h after patch application. The main
disadvantage of transdermal delivery is that therapeutic
plasma levels are obtained very slowly, 6–8 h after
application in the case of scopolamine.15–17 Thus, the use
of TTS-scopolamine poses a problem when immediate
treatment is required. Furthermore, the transdermal
administration of scopolamine also has other limitations.
For example, the peak plasma concentration (Cmax) is not
reached until 12–16 h after dosing. Moreover, this route
provides unnecessary prolonged blood levels that result in
a significant side effect profile which includes dry mouth,
drowsiness, and blurred vision.18
Nasal administration gained attention of many phar-
maceutical scientists due to its great potential utility for
rapid drug delivery. It offers an attractive alternative for
drugs with limited oral bioavailability that are destroyed
by gastrointestinal fluids, or highly susceptible to hepatic
first-pass or gut-wall metabolism.19 Results of earlier
investigations from our laboratory indicated that while
bioavailability of orally administration scopolamine was
poor and variable, intranasal administration resulted in a
fast, reliable, and more complete absorption of the
drug.9,20 Klocker et al21 also reported that scopolamine
nasal spray is an effective and safe treatment for motion
sickness, with a fast onset of action within 30minutes
after administration. More recently, Renner et al22 also
reported that pharmacokinetics and pharmacodynamics of
scopolamine depend on the dosage form.
INSCOP offers less variability of systemic concen-
trations unlike oral administration with higher concen-
trations of the drug achieved more rapidly due to the fast
absorption.9,22 The purpose of this study was to evaluate
dose linearity of pharmacokinetics of this INDT
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formulation for intranasal administration per FDA
requirement of IND pharmaceutical preparations. This
IND formulation is aimed at providing a rapidly acting,
reliable, safe, and efficacious alternative for the treatment
and prevention of motion sickness experienced by
astronauts in space. Other target populations may be
benefited from the use of this novel formulation as well,
most notably, military aviators, military, and commercial
seafarers. The formulation once approved for market
release by the FDA is expected to facilitate administration
of lower than normal therapeutic doses with no side
effects in Space and on Earth.
Results of this study clearly demonstrate that INSCOP
was rapidly absorbed with measurable concentrations in
plasma within 5minutes after administration of all three
doses in all the subjects, reaching maximum concen-
trations at 1.2–1.3 hours post dose (Table 2). Absorption
and bioavailability appear to be linear at the administered
dose range as indicated by Cmax and AUC (Figures 2a and
2c). Ratios of body weight normalized AUC and Cmax
with dose (Figures 2b and 2d) are consistent confirming
dose linear PK of INSCOP at 0.1–0.4mg dose range
(Figure 2). These results indicate consistent linearity of
absorption and bioavailability at all three doses,
Figure 3. Urinary excretion rate profiles of scopolamine after administration of INSCOP to normal subjects (mean SE). (a) Mean urinary excretion
rates of scopolamine in all subjects (n¼ 12), (b) mean urinary excretion rates of scopolamine in male subjects (n¼ 6), (c) mean urinary excretion rates
of scopolamine in female subjects (n¼ 6).
Table 3. Urinary Excretion of Scopolamine and Scopolamine Glucuronide After INSCOP Administration to Normal Subjects
Parameters Dose (0.1mg) Dose (0.2mg) Dose (0.4mg)
Mean SD Unit All Female Male All Female Male All Female Male
N 12 6 6 12 6 6 12 6 6
Urinary excretion of scopolamine
Xu mg 1.4 0.6 1.5 0.5 1.4 0.7 3.2 1.6 3.5 1.9 2.9 1.0 6.3 2.4 6.4 1.9 6.2 2.8
PDEx % 1.3 0.8 1.2 0.7 1.3 1.0 1.4 0.9 1.5 1.1 1.4 0.7 1.4 0.6 1.5 0.6 1.2 0.6
AUXu h*mg/mL 1.3 0.6 1.3 0.6 1.3 0.7 2.9 1.6 3.1 1.8 2.7 1.0 6.1 2.6 6.4 2.0 5.9 1.7
Urinary excretion of scopolamine glucuronide
Xu mg 4.5 1.6 4.5 2.1 4.5 2.4 11.2 7.5 14.3 9.1 8.1 7.6 20.8 9.7 19.3 4.3 22.6 14.5
PDEx % 4.5 1.6 4.5 2.2 4.5 2.4 4.2 4.0 4.9 4.3 3.5 3.5 5.2 2.5 4.8 1.1 5.6 3.7
AUXu h*mg/mL 4.2 1.4 4.9 2.4 3.5 1.7 10.5 7.2 10.9 6.2 10.2 4.6 21.3 9.5 20.5 5.0 22.1 7.0
Xu, total amount excreted in the urine; PDEx, percent of dose excreted in the urine; AUXu, area under the urinary excretion rate-time curve; SD, standard
deviation.
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suggesting safety and reliability of treatment in this dose
range without the potential for adverse side effects.
Increases in both observed and derived Cmax, observed
AUC at last time point along with extrapolated AUC at
time infinity were also linear with dose (Table 2). This
dose linearity of PK in addition to the short half-life (1.1–
1.4 hours) may allow administration of multiple doses
without significant side effects. Results from an earlier
study by authors9 indicated that an aqueous formulation of
INSCOP achieved higher Cmax and AUC values,
compared to those of an equivalent oral dose. Both
Cmax and AUC were higher after administration of
aqueous drops compared to those in this study (1.6 0.2
vs. 0.3 0.1 ng/mL and 2.8 0.3 vs. 1.3 0.6 ng*h/mL,
respectively) suggesting that the aqueous formulation
may offer more efficient absorption after intranasal
administration. The pH of the gel was slightly lower
than aqueous drops (3.5 versus 4) which may be a reason
for lower absorption from the gel since Ahmed et al23
reported that better bioavailability of scopolamine can be
achieved by increasing the pH of nasal formulations.
Simmons et al24 in a double blind, placebo controlled
clinical efficacy trial with INSCOP using Human
Disorientation Device (HDD) for inducing motion
sickness in aviation candidate subjects (mean age 23.5
y), collected four blood samples over 1.5 hours post dose
to estimate drug levels associated with efficacy of
treatment. They reported Cmax and AUC values of
0.15 ng/mL and 0.1 ng.h/mL, respectively. These values
are lower than those from our results (0.3 ng/mL and
1.3 ng.h/mL, respectively). However, Tmax values in both
studies are similar (1.3 hours post dose). These results
lead us to believe that both Cmax and AUC may be
underestimated in their study due to lack of adequate
sampling duration. Additionally, age of subject popula-
tion and artificial motion environment could also
contribute to differences in disposition of scopolamine
in the two studies.
With respect to sex differences in pharmacokinetics of
scopolamine, Ebert et al25 reported that Cmax was higher
in males than in females after intravenous infusion of
0.5mg dose for 15minutes suggesting that females may
need higher doses than males to achieve minimum
effective concentration. Results from our study showed
sex differences in some of the parameter estimates only at
the higher dose of 0.4mg. Mean Cmax was lower in males
than in females (P< 0.05), concurrently, clearance and
volume of distribution values in males were higher than in
females (P< 0.05). However, no significant difference in
the AUC between males and females was detected by
Wilcoxon rank-sum (Mann–Whitney) test (P¼ 0.08),
most likely due to the highest degree of variability
observed with dose dispensed for 0.4mg treatment with a
mean dose of 0.5 0.3mg ranging between 0.3 and
1.2mg. Men and Venitz26 also reported similar sex
differences in volume of distribution and half-life with
males having a 45% higher Vdss and a 26% longer t1/2
than females after a 6.7mg/kg intravenous dose. The
reported sex differences in the pharmacokinetic param-
eters of scopolamine may be attributed to possible
physical and physiological differences between sexes,
e.g., body weight, ratio of muscle tissue and body fat
which could influence volume distribution and clearance,
and possible differences in entero-hepatic metabolizing
enzymes. While these authors also reported significant
age-related differences in clearance and volume of
distribution with elderly subjects having higher values
than those in the young attributable to changes in plasma/
tissue protein binding and/or extra-hepatic metabolism,
no significant difference in AUC was observed in our
study when subjects were divided into two age groups of
21–29 and 33–47 years. Age range for subjects in our
study was intentionally kept narrow (21–47 years) in
order to match age distribution of astronaut population.
Urinary recovery of unchanged scopolamine and its
metabolite, glucuronide conjugate (Table 3), suggest that
hepatic metabolism may be an important pathway of
elimination of scopolamine after administration. Cumula-
tive amount of scopolamine and glucuronide conjugate
excreted in the urine increased linearly with dose, with
amounts excreted higher after 0.4mg dose. Concurrently,
fraction of dose excreted as scopolamine and glucuronide
conjugate in the urine were consistent and were not
significantly different among the three dose levels with
excretion ranging between 1.3%and1.4% for scopolamine
and 4.2% and 5.2% for glucuronide conjugate (Table 3) . It
is noteworthy that the cumulative percentage of dose
excreted as scopolamine and glucuronide conjugate in the
urine accounts for less than 10% of the administered dose
for all three dose levels indicating the involvement of other
significant metabolic pathways for scopolamine elimina-
tion in humans. Kentala et al27 reported that following
incubation of urine samples with b-glucuronidase and
sulfatase, total scopolamine concentrations in the urine
consisting parent drug and metabolites (glucuronide and
sulfate conjugates) increased almost seven times without a
significant increase in parent compound concentrations at
all sample collection time points for 12 hours post dosing.
These results indicate that glucuronide and sulfate
conjugation are important metabolic pathways of scopol-
amine elimination in humans. In light of the fact that only
less than 5.2%dose is excreted as glucuronide conjugate in
our study, it is prudent to expect that sulfate conjugation is
another significant metabolic pathway of scopolamine in
human subjects. These results of overall low recovery of
administered dose in this study also support existence of
other extra-hepatic metabolism pathways of scopolamine
suggested by earlier reports on the elimination of
scopolamine.25 No significant difference in urinary
excretion rate of scopolamine and scopolamine
Wu et al 201
glucuronide across sexes was observed which is in
agreement with earlier reports.25
Most pharmacodynamic studies with scopolamine thus
far focused on the CNS effects of the drug. Pharmacody-
namic measurements after intravenous and intramuscular
scopolamine administration (0.5mg scopolamine hydro-
bromide over a period of 15minutes, and 0.5mg in the
upper right arm, respectively) indicated no interday
variability of the baseline values of EEG.28 Scopolamine
was reported to produce a dose- and time-dependent
impairment of memory and attention.29 However, all of
these studies used higher dose of parenteral administra-
tion. We reported significant suppression of salivary flow
rate after intranasal administration of a low dose.9 A
significant decrease in diastolic blood pressure after
administration of intranasal scopolamine (0.4mg or
0.2%) was also reported.24,21
Limited information on the effective scopolamine
concentrations for motion sickness treatment suggest that
the mean scopolamine concentration in plasma required
for seasickness prevention is 160 pg/mL.30 Recent results
on efficacy of INSCOP to prevent motion sickness
symptoms using motion sickness simulation device HDD
suggested that 0.4mg of intranasal scopolamine delays
the onset of motion sickness and that the effect is both
statistically and clinically significant as indicated by
significantly more head movements tolerated by subjects
after receiving 0.4mg of intranasal scopolamine than after
receiving a placebo.24 Klocker et al21 also showed that
scopolamine nasal spray at a concentration of 0.2% was
statistically superior to both placebo and dimenhydrinate
in reducing seasickness score induced by whole body
vibrations by a rotating chair. Neither of these studies,
however, examined pharmacodynamics of scopolamine.
The number of intranasally administered drugs
approved for marketing in the US by the FDA is limited,
most of which are aqueous spray formulations, and
reports on dose escalation studies in humans are available
for only a handful of drugs that include sublingual
desmopressin,31 intranasal insulin,32 nasal spray of
zolmitriptan,33 and intranasal ganirelix.34
A gel formulation of Vitamin B12, Nascobol, was
marketed by NASTECH which was subsequently
abandoned and distributed at present as a spray formula-
tion. Intranasal gel formulations are expected to provide
increased retention time at the site of absorption, the nasal
mucosal membrane, to enhance absorption and bioavail-
ability compared to aqueous mists or sprays. However,
gel formulations have inherent problems of inconsistent
dose delivery resulting from sub-optimal specific gravity/
viscosity characteristics and drug wastage due to priming
volume requirements. Additionally, contamination with
scopolamine during priming process of gel formulation
can cause undesirable ocular side effects. Although
the current gel formulation and the delivery devices
performed satisfactorily in the reduced gravity environ-
ment of parabolic flight suggesting that the dosage form
may be suitable for the treatment of SMS, certain aspects
of formulation like higher viscosity (1945–2050 cP) and
lower than optimal pH are undesirable. While the current
study found desirable pharmacokinetics of escalating
doses of INSCOP, irregular dose delivery and excessive
priming of the pump actuator required on occasions must
be addressed for optimizing performance and efficacy of
INSCOP.
In conclusion, INSCOP offers an attractive therapeutic
alternative for motion sickness in light of its reliable and
efficacious delivery characteristics in addition to being a
simple and cost-effective formulation of an age-old drug
with long standing safety record for use in modern
medicine. It is expected that intranasal administration can
provide higher concentrations more rapidly than oral
doses that can enhance speed of onset and duration of
therapeutic activity. Further, since nausea and vomiting
are common symptoms of motion sickness, which can
hinder absorption from an oral dose, exasperated by poor
bioavailability due to extensive first pass metabolism after
oral administration, it is hoped that treatment of motion
sickness both on Earth and in space can be efficaciously
managed before and after the onset of symptoms.
Presently, clinical trials are underway with a modified
aqueous spray formulation that will offset some of the
aforementioned disadvantages encountered with the gel
formulation.
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